Evaluation of Clinical Pharmacist Led Guidance on Treatment Outcomes, Treatment Adherence & Quality of Life Among T2DM Patients Attending Endocrinology Out Patient Department in a Tertiary Care Hospital

Clinical pharmacist‐led guidance was evaluated in a 6‑month prospective observational study of 90 T2DM patients at a tertiary care hospital. Participants were distributed into test (Group A; n = 45) and control (Group B; n = 45) groups. Group A received structured clinical pharmacist counselling on medication regimens, adherence, lifestyle modifications, and ADR monitoring, whereas Group B received standard care. Outcomes measured at baseline and 2 months included glycaemic profiles, lipid profile, medication adherence (MARS‑10), and quality of life (WHOQOL‑BREF). Group A exhibited significant improvements in FBS, PPBS, medication adherence, and quality of life physical and psychological domains. HbA1c and lipid profile showed favourable but non‑significant trends. No major ADRs were reported. These findings support integration of pharmacist‑led guidance and care in chronic disease management.